Hepion Pharmaceuticals signs USD 500,000 secured convertible note deal with Gravitas Capital

• Hepion Pharmaceuticals entered a USD 500,000 secured convertible note purchase agreement with Gravitas Capital on Sept. 3, 2026.
• The secured convertible note carries 8% annual interest payable in kind, with maturity on Sept. 3, 2027.
• Conversion becomes available upon shareholder approval to increase authorized common shares, at USD 0.04 per share.
• Gravitas also received a warrant for 12,500,000 common shares, exercisable at USD 0.06 through Sept. 3, 2031, subject to approval.
• The note is secured by all company assets under a separate security agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-041801), on September 08, 2026, and is solely responsible for the information contained therein.